Esomeprazole Induced Healing of Gastroesophageal Reflux Disease is Unrelated to the Genotype of CYP2C19
G Treiber, U Klotz, U Hofmann, E Schaeffeler, A Leodolter, P Malfertheiner, M Schwab · Zeitschrift für Gastroenterologie · 2006 · Heft 04
Bibliografische Angaben
Zusammenfassung
Background & Aims: Clinical outcome of acid related disorders treated by proton pump inhibitors (PPI) might be dependent on the polymorphically expressed CYP2C19 which is involved in PPI metabolism. We tested whether esomeprazole (ESO) induced healing of gastroesophageal reflux disease (GERD) is related to CYP2C19 genotype. Methods: 205 patients with GERD (Los Angeles classification grade A/B) were treated prospectively with 40mg of ESO daily for 4 weeks, and then stratified according to endoscopic outcome (healed vs. unhealed group). The frequency of CYP2C19 genotypes was determined as the primary outcome measu…
